By Brandi Felser, Executive Director In my very first days on the job as the new Executive Director of the Sarcoma Foundation of America, I had the opportunity to experience first-hand the power of the sarcoma community. For the first time ever, the US Food and Drug Administration (FDA) was reviewing for approval a proposed drug for the treatment of epithelioid sarcoma, a particularly rare and aggressive subtype of sarcoma. Epithelioid sarcoma has few effective treatment options and patients are often left with little or no hope for long-term survival. As a part of the approval process, the benefits of…  Read More »